0000000000514282

AUTHOR

C. Tortorella

showing 5 related works from this author

A multicenter survey on access to care in Multiple Sclerosis-related trigeminal neuralgia

2021

The prevalence of trigeminal neuralgia (TN) in patients with Multiple Sclerosis (MS) is higher than in the general population and its management can be particularly challenging due to a number of reasons including high recurrence rates, lack of MS-specific treatment guidelines and uncertainties about pain pathophysiology. Aim of this cross-sectional, multicentre survey was to gather information on the current treatment modalities and options of MS-related TN across 23 Italian MS centres. Initial medical management (carbamazepine or oxcarbazepine) of MS-related TN was fairly homogeneous throughout Italian centres. The most commonly available surgical procedure was microvascular decompression…

medicine.medical_specialtyMultiple Sclerosismultiple sclerosis; trigeminal neuralgiaCross-sectional studymedicine.medical_treatmentPopulationMicrovascular decompressionHealth Services Accessibility03 medical and health sciences0302 clinical medicineRetrospective StudieTrigeminal neuralgiaMultiple SclerosimedicineHumans030212 general & internal medicineIntensive care medicineeducationOxcarbazepineRetrospective StudiesCross-Sectional Studieeducation.field_of_studybusiness.industryMultiple sclerosisRetrospective cohort studyTrigeminal Neuralgiamedicine.diseaseCross-Sectional StudiesTreatment OutcomeItalyNeurologyMulticenter surveyNeurology (clinical)businessMultiple Sclerosis; Trigeminal neuralgia; Cross-Sectional Studies; Health Services Accessibility; Humans; Italy; Retrospective Studies; Treatment Outcome; Multiple Sclerosis; Trigeminal NeuralgiaTrigeminal neuralgia030217 neurology & neurosurgeryHumanmedicine.drugJournal of the Neurological Sciences
researchProduct

Real-life impact of early interferonβ therapy in relapsing multiple sclerosis

2009

Objective: Recent findings support greater efficacy of early vs. delayed interferon beta (IFN) treatment in patients with a first clinical event suggestive of multiple sclerosis (MS). We aimed to evaluate the effectiveness of early IFN treatment in definite relapsing-remitting MS (RRMS) and to assess the optimal time to initiate IFN treatment with regard to the greatest benefits on disability progression. Methods: A cohort of 2,570 IFN-treated RRMS patients was prospectively followed for up to 7 years in 15 Italian MS Centers. A Cox proportional hazards regression model adjusted for propensity score (PS) quintiles was used to assess differences between groups of patients with early vs. dela…

medicine.medical_specialtyExpanded Disability Status Scalebusiness.industryMultiple sclerosisHazard ratiomedicine.diseaseSurgeryCentral nervous system diseaseNeurologyInternal medicinePropensity score matchingCohortmedicineObservational studyNeurology (clinical)Unmeasured confoundingbusinessAnnals of Neurology
researchProduct

Informing MS patients on treatment options: a consensus on the process of consent taking

2020

Abstract\ud In the last years, change in multiple sclerosis (MS) therapeutic scenario has highlighted the need for an improved doctor-patient communication in advance of treatment initiation in order to allow patient’s empowerment in the decision-making process.\ud Aims\ud The aims of our project were to review the strategies used by Italian MS specialists to inform patients about treatment options and to design a multicentre shared document that homogenizes the information about disease-modifying treatment (DMTs) and the procedure of taking informed consent in clinical practice.\ud Results\ud The new resource, obtained by consensus among 31 neurologists from 27 MS Centres in Italy with the…

medicine.medical_specialtyConsensusProcess (engineering)media_common.quotation_subjectDermatologyDisease modifying treatment; Informed consent; Multiple sclerosisMultiple sclerosis03 medical and health sciences0302 clinical medicineResource (project management)Informed consentDisease modifying treatmentmedicineHumans030212 general & internal medicineInformed consentEmpowermentmedia_commonPhysician-Patient Relationsbusiness.industryTreatment optionsGeneral MedicineClinical PracticePsychiatry and Mental healthItalyFamily medicineDisease modifying treatment; Informed consent; Multiple sclerosis; Consensus; Humans; Italy; Physician-Patient Relations; Informed Consent; Multiple SclerosisSettore MED/26 - NeurologiaNeurology (clinical)Decision processbusiness030217 neurology & neurosurgery
researchProduct

Real-life impact of early interferon beta therapy in relapsing multiple sclerosis.

2009

OBJECTIVE: Recent findings support greater efficacy of early vs. delayed interferon beta (IFNbeta) treatment in patients with a first clinical event suggestive of multiple sclerosis (MS). We aimed to evaluate the effectiveness of early IFNbeta treatment in definite relapsing-remitting MS (RRMS) and to assess the optimal time to initiate IFNbeta treatment with regard to the greatest benefits on disability progression. METHODS: A cohort of 2,570 IFNbeta-treated RRMS patients was prospectively followed for up to 7 years in 15 Italian MS Centers. A Cox proportional hazards regression model adjusted for propensity score (PS) quintiles was used to assess differences between groups of patients wit…

AdultMaleTime FactorsMultiple Sclerosis; Interferon betaInterferon-beta.Interferon betaCohort StudiesYoung AdultMultiple Sclerosis Relapsing-RemittingTreatment Outcomeobservational study multiple sclerosis interferon treatment earlySickness Impact ProfileMultiple SclerosiQuality of LifeHumansFemaleSettore MED/26 - NeurologiaProspective StudiesFollow-Up Studies
researchProduct

The diagnosis of multiple sclerosis: pinpointing the concept of "no better explanation"

2014

diagnosisMultiple sclerosiSettore MED/26 - Neurologiamultiple sclerosis
researchProduct